The association of Sars-CoV-2 infection and tuberculosis disease with unfavorable treatment outcomes
A systematic review
Bibliographic Data
| ID | 19595043 |
|---|---|
| Authors | Nirma Khatri Vadlamudi (0000-0001-5513-7926), C Andrew Basham (0000-0003-0506-7936), Jason C Johnston (0000-0002-8879-4989), Faiz Ahmad Khan, Giovanni Battista Migliori (0000-0002-2597-574X), Rosella Centis (0000-0002-8551-3598), Lia D’Ambrosio, Waasila Jassat (0000-0003-4279-3056), Mary-Ann Davies, Kevin Schwartzman (0000-0002-3354-1159), Jonathon R Campbell (0000-0003-2341-2166) |
| Editors | Julio Croda (0000-0002-6665-6825) |
| Year | 2023 |
| Volume | 3 |
| Issue | 7 |
| Pages | e0002163 |
| Publication date | 2023-07-19 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | PLOS Global Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2767-3375 • E-ISSN: 2767-3375 |
| Publisher | Public Library of Science (PLoS) (PUBLISHER) |
| DOI | 10.1371/journal.pgph.0002163 |
| Language | EN |
| References cited | 22 |
Background Whether SARS-CoV-2 infection and its management influence tuberculosis (TB) treatment outcomes is uncertain. We synthesized evidence on the association of SARS-CoV-2 coinfection ( Coinfection Review ) and its management ( Clinical Management Review ) on treatment outcomes among people with tuberculosis (TB) disease. Methods We systematically searched the literature from 1 January 2020 to 6 February 2022. Primary outcomes included: unfavorable (death, treatment failure, loss-to-follow-up) TB treatment outcomes ( Coinfection and Clinical Management Review ) and/or severe or critical COVID-19 or death ( Clinical Management Review ). Study quality was assessed with an adapted Newcastle Ottawa Scale. Data were heterogeneous and a narrative review was performed. An updated search was performed on April 3, 2023. Findings From 9,529 records, we included 11 studies and 7305 unique participants. No study reported data relevant to our review in their primary publication and data had to be contributed by study authors after contact. Evidence from all studies was low quality. Eight studies of 5749 persons treated for TB (286 [5%] with SARS-CoV-2) were included in the Coinfection Review . Across five studies reporting our primary outcome, there was no significant association between SARS-CoV-2 coinfection and unfavorable TB treatment outcomes. Four studies of 1572 TB patients—of whom 291 (19%) received corticosteroids or other immunomodulating treatment—were included in the Clinical Management Review , and two addressed a primary outcome. Studies were likely confounded by indication and discordant findings existed among studies. When updating our search, we still did not identify any study reporting data relevant to this review in their primary publication. Interpretation No study was designed to answer our research questions of interest. It remains unclear whether TB/SARS-CoV-2 and its therapeutic management are associated with unfavorable outcomes. Research is needed to improve our understanding of risk and optimal management of persons with TB and SARS-CoV-2 infection. Trial registration Registration : PROSPERO ( CRD42022309818 )
| Highly cited | No |
|---|